
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay was developed and was capable of detection at the requisite sensitivity and enabled meaningful interpretation of PK data obtained from the preclinical animal model.






